Key result
In patients with AMI-CS, end-stage renal disease was an independent predictor of higher in-hospital mortality compared to no CKD (OR 1.25; 95% CI 1.21-1.31; p<0.001).
Why the study?
Data on acute myocardial infarction with cardiogenic shock stratified by chronic kidney disease stages were limited.
Does advanced chronic kidney disease or end-stage renal disease affect in-hospital mortality and the use of evidence-based therapies in patients with acute myocardial infarction and cardiogenic shock?
Cohort (n=372,412)
Yes
Does advanced chronic kidney disease or end-stage renal disease affect in-hospital mortality and the use of evidence-based therapies in patients with acute myocardial infarction and cardiogenic shock?
Odds Ratio: 1.25 (95% CI 1.21–1.31)
p-value: p=<0.001
In patients with AMI-CS, advanced CKD and ESRD are associated with significantly lower utilization of evidence-based therapies, and ESRD is an independent predictor of increased in-hospital mortality.
Background: There are limited data on acute myocardial infarction with cardiogenic shock (AMI-CS) stratified by chronic kidney disease (CKD) stages. Objective: To assess clinical outcomes in AMI-CS stratified by CKD stages. Methods: A retrospective cohort of AMI-CS during 2005–2016 from the National Inpatient Sample was categorized as no CKD, CKD stage-III (CKD-III), CKD stage-IV (CKD-IV) and end-stage renal disease (ESRD). CKD-I/II were excluded. Outcomes included in-hospital mortality, use of coronary angiography, percutaneous coronary intervention (PCI) and mechanical circulatory support (MCS). We also evaluated acute kidney injury (AKI) and acute hemodialysis in non-ESRD admissions. Results: Of 372,412 AMI-CS admissions, CKD-III, CKD-IV and ESRD comprised 20,380 (5.5%), 7367 (2.0%) and 18,109 (4.9%), respectively. Admissions with CKD were, on average, older, of the White race, bearing Medicare insurance, of a lower socioeconomic stratum, with higher comorbidities, and higher rates of acute organ failure. Compared to the cohort without CKD, CKD-III, CKD-IV and ESRD had lower use of coronary angiography (72.7%, 67.1%, 56.9%, 61.1%), PCI (53.7%, 43.8%, 38.4%, 37.6%) and MCS (47.9%, 38.3%, 33.3%, 34.2%), respectively (all p < 0.001). AKI and acute hemodialysis use increased with increase in CKD stage (no CKD–38.5%, 2.6%; CKD-III–79.1%, 6.5%; CKD-IV–84.3%, 12.3%; p < 0.001). ESRD (adjusted odds ratio [OR] 1.25 [95% confidence interval {CI} 1.21–1.31]; p < 0.001), but not CKD-III (OR 0.72 [95% CI 0.69–0.75); p < 0.001) or CKD-IV (OR 0.82 [95 CI 0.77–0.87] was predictive of in-hospital mortality. Conclusions: CKD/ESRD is associated with lower use of evidence-based therapies. ESRD was an independent predictor of higher in-hospital mortality in AMI-CS.
No takes yet. Share an insight, caveat, or question.
Vallabhajosyula et al. (2020) conducted a cohort in Acute myocardial infarction with cardiogenic shock (AMI-CS) (n=372,412). End-stage renal disease (ESRD) vs. No CKD was evaluated on In-hospital mortality (OR 1.25, 95% CI 1.21-1.31, p=<0.001). In patients with AMI-CS, end-stage renal disease was an independent predictor of higher in-hospital mortality compared to no CKD (OR 1.25; 95% CI 1.21-1.31; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: